Cargando…
Enzyme-Enhanced Codelivery of Doxorubicin and Bcl-2 Inhibitor by Electrospun Nanofibers for Synergistic Inhibition of Prostate Cancer Recurrence
One of the great challenges of postoperative prostate cancer management is tumor recurrence. Although postoperative chemotherapy presents benefits to inhibit unexpected recurrence, it is still limited due to the drug resistance or intolerable complications of some patients. Electrospun nanofiber, as...
Autores principales: | Liu, Zheng, Luo, Xing, Mo, Yongxin, Zhao, Pengkai, Wang, Haixia, Fang, Youqiang, Xu, Yanteng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610395/ https://www.ncbi.nlm.nih.gov/pubmed/36297356 http://dx.doi.org/10.3390/ph15101244 |
Ejemplares similares
-
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
por: Li, Ke, et al.
Publicado: (2019) -
Codelivery of Doxorubicin and Paclitaxel by Cross-Linked
Multilamellar Liposome Enables Synergistic Antitumor Activity
por: Liu, Yarong, et al.
Publicado: (2014) -
Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer
por: Wang, Zhicheng, et al.
Publicado: (2021) -
A Modular Coassembly Approach to All-In-One Multifunctional Nanoplatform for Synergistic Codelivery of Doxorubicin and Curcumin
por: Yang, Muyang, et al.
Publicado: (2018) -
Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
por: Wu, Bo, et al.
Publicado: (2017)